AP2012006094A0 - Treatment and prevention of dengue virus infections. - Google Patents

Treatment and prevention of dengue virus infections.

Info

Publication number
AP2012006094A0
AP2012006094A0 AP2012006094A AP2012006094A AP2012006094A0 AP 2012006094 A0 AP2012006094 A0 AP 2012006094A0 AP 2012006094 A AP2012006094 A AP 2012006094A AP 2012006094 A AP2012006094 A AP 2012006094A AP 2012006094 A0 AP2012006094 A0 AP 2012006094A0
Authority
AP
ARIPO
Prior art keywords
prevention
treatment
dengue virus
virus infections
infections
Prior art date
Application number
AP2012006094A
Other languages
English (en)
Inventor
Dongcheng Dai
Robert Jordan
Dennis E Hruby
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of AP2012006094A0 publication Critical patent/AP2012006094A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/625Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AP2012006094A 2009-06-30 2010-06-22 Treatment and prevention of dengue virus infections. AP2012006094A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22177309P 2009-06-30 2009-06-30
PCT/US2010/039462 WO2011002635A1 (en) 2009-06-30 2010-06-22 Treatment and prevention of dengue virus infections

Publications (1)

Publication Number Publication Date
AP2012006094A0 true AP2012006094A0 (en) 2012-02-29

Family

ID=43411375

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006094A AP2012006094A0 (en) 2009-06-30 2010-06-22 Treatment and prevention of dengue virus infections.

Country Status (13)

Country Link
US (1) US20150150852A1 (xx)
EP (1) EP2448410A4 (xx)
JP (1) JP2012532102A (xx)
KR (1) KR20120049852A (xx)
CN (1) CN102469788A (xx)
AP (1) AP2012006094A0 (xx)
AU (1) AU2010266570A1 (xx)
BR (1) BRPI1009034A2 (xx)
CA (1) CA2763194A1 (xx)
IL (1) IL216605A (xx)
MX (1) MX336687B (xx)
WO (1) WO2011002635A1 (xx)
ZA (1) ZA201109187B (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011274323B2 (en) 2010-07-02 2015-08-06 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as HIV antiviral compounds
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
CN102731394A (zh) * 2011-04-12 2012-10-17 中国科学院上海药物研究所 取代的喹啉-2-甲醛-苯腙类化合物及其制备方法和用途
AP2015008931A0 (en) 2011-04-21 2015-12-31 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2013036749A1 (en) * 2011-09-07 2013-03-14 University Of Kansas Hcv helicase inhibitors and methods of use thereof
KR20140070631A (ko) 2011-09-30 2014-06-10 키네타, 인크. 항바이러스 화합물
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 B型肝炎抗病毒劑
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
CA2850881C (en) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
EA027280B1 (ru) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
CN102988352A (zh) * 2012-11-19 2013-03-27 何晓涛 Aphanamixoid A在治疗登革病毒感染药物中的应用
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (xx) 2013-07-25 2018-07-21
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4141002A1 (en) 2015-11-19 2023-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3394033T3 (pl) 2015-12-22 2021-05-31 Incyte Corporation Związki heterocykliczne jako immunomodulatory
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
MX2018016273A (es) 2016-06-20 2019-07-04 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106349184B (zh) * 2016-08-08 2021-10-26 江西师范大学 2-(邻烷基芳基)苯并噻唑的制备方法
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
CN110582493B (zh) 2016-12-22 2024-03-08 因赛特公司 作为免疫调节剂的苯并噁唑衍生物
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
KR20240038149A (ko) 2017-04-26 2024-03-22 바실리어 파마슈티카 인터내셔널 리미티드 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정
WO2019004825A1 (en) 2017-06-28 2019-01-03 Rijksuniversiteit Groningen TOMATIDINE AND ANALOGUES THEREOF FOR USE AS ANTIVIRAL AGENT
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
SG11202009440WA (en) 2018-03-30 2020-10-29 Incyte Corp Heterocyclic compounds as immunomodulators
DK3790877T3 (da) 2018-05-11 2023-04-24 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
KR102146741B1 (ko) * 2018-10-31 2020-08-21 계명대학교 산학협력단 항바이러스 조성물
CN109265412B (zh) * 2018-11-19 2020-06-02 大连大学 一种用于检测氟离子的探针化合物及其检测方法
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
JP2022553284A (ja) * 2019-10-24 2022-12-22 小野薬品工業株式会社 Trek(twik関連k+チャネル)チャネル機能の阻害剤
TW202120504A (zh) 2019-11-11 2021-06-01 美商英塞特公司 Pd-1/pd-l1 抑制劑之鹽及結晶型
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Pd—1/pd—l1抑制劑之結晶形式
AU2021373044A1 (en) 2020-11-06 2023-06-08 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431809A (en) * 1981-04-13 1984-02-14 Eli Lilly And Company Antibiotic A-33853 derivatives
CA1299176C (en) * 1985-07-02 1992-04-21 Guy Dominic Diana Process for preparing isoxazole and furan derivatives
CN1171887C (zh) * 1999-06-28 2004-10-20 詹森药业有限公司 呼吸道合胞病毒复制抑制剂
MXPA05012101A (es) * 2003-05-09 2006-02-08 Boehringer Ingelheim Int Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.
WO2006121467A2 (en) * 2004-11-22 2006-11-16 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives for treating flaviridae viruses
EP1976829A2 (en) * 2005-12-12 2008-10-08 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
EP1971599A1 (en) * 2005-12-22 2008-09-24 SmithKline Beecham Corporation Antiviral 2-carboxy-thiophene compounds
GB0602046D0 (en) * 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
WO2008017688A1 (en) * 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation

Also Published As

Publication number Publication date
CA2763194A1 (en) 2011-01-06
US20150150852A1 (en) 2015-06-04
JP2012532102A (ja) 2012-12-13
WO2011002635A1 (en) 2011-01-06
BRPI1009034A2 (pt) 2019-09-24
KR20120049852A (ko) 2012-05-17
ZA201109187B (en) 2013-05-29
IL216605A (en) 2015-04-30
MX336687B (es) 2016-01-28
MX2011012983A (es) 2012-01-12
AU2010266570A1 (en) 2012-01-19
EP2448410A4 (en) 2013-12-18
IL216605A0 (en) 2012-02-29
CN102469788A (zh) 2012-05-23
EP2448410A1 (en) 2012-05-09

Similar Documents

Publication Publication Date Title
AP2012006094A0 (en) Treatment and prevention of dengue virus infections.
AP2011005901A0 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections.
IL253038A0 (en) Preparations and methods for the treatment or prevention of infections. my voice
ZA201204625B (en) Analogues for the treatment or prevention of flavivirus infections
IL217503A0 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
IL209380A0 (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
EP2491033A4 (en) AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
ZA201101814B (en) Prevention, treatment and diagnosis of p.gingivalis infection
ZA201105343B (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection
EP2521554A4 (en) SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
IL202126A0 (en) Treatment and prevention of influenza
BR112013015771A2 (pt) derivados de ciclosporina para o tratamento e a prevenção de uma infecção viral
EP2928470A4 (en) THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
HK1248535A1 (zh) 感染的治療或預防
SG10201704908SA (en) Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
EP2217573A4 (en) TREATMENT AND PREVENTION OF VIRUS INFECTIONS
HK1201181A1 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
EP2723372A4 (en) PROTECTION AGAINST DENGUE VIRUS AND PREVENTION AGAINST HEAVY DENGUE ILLNESSES
HK1174256A1 (en) Treatment and prevention of hiv infection hiv
AP2012006241A0 (en) Use of ferroquine in the treatment or prevention of malaria.
HU0900298D0 (en) Immungenic nanomedicine for the prevention and treatment of allergy
GB0919711D0 (en) Treatment of viral infections
GB0913914D0 (en) Treatment of viral infections
GB0811950D0 (en) Disease prevention and treatment
AU2009903052A0 (en) Prevention, treatment and diagnosis of P.gingivalis infection